Quince Therapeutics is advancing its pivotal Phase 3 NEAT trial in Ataxia-Telangiectasia, targeting 6–9 year-old patients. The study is 90% powered to demonstrate statistical significance on its primary efficacy endpoints and incorporates revised inclusion criteria to address design limitations from prior studies. Regulatory interactions with the FDA and EMA have confirmed the protocol’s acceptability and a streamlined path to potential accelerated approval in an orphan indication estimated to exceed $1 billion in peak annual revenue.

A consensus of seven equity research analysts assigns Quince Therapeutics a Moderate Buy rating. Among them, four maintain buy recommendations, one issues a strong buy, one holds, and one advises sell. Recent research reports include an upgraded target valuation from a leading independent brokerage and a reaffirmation of market-outperform status by a major global bank. The average twelve-month target across these analysts stands at approximately $8.00 per share.

Recent filings show a notable uptick in institutional ownership, with several quantitative and growth-oriented funds adding to their positions during the second and third quarters. One global arbitrage manager raised its stake by 158%, while a specialized healthcare allocator and a boutique value fund each expanded holdings by over 20%. These shifts suggest growing confidence among professional investors as the company approaches its pivotal NEAT trial readout.